Innovative Treatment Approaches for Rheumatoid ArthritisPeter M. Brooks, Daniel E. Furst |
Contents
PrefaceD E FURST P M BROOKS | 618 |
Anticytokine therapy in rheumatoid arthritis | 633 |
Tcell regulation | 653 |
Copyright | |
8 other sections not shown
Common terms and phrases
allogeneic Annals anti-CD4 anti-inflammatory antigen Arthritis and Rheumatism auranofin azathioprine biological agents bone marrow transplantation British Journal cartilage Clinical Rheumatology clinical trials combination therapy compared control group controlled trial cyclosporin cytokine D-penicillamine decreased diclofenac diet dietary disease activity DMARD dose double-blind drug effect efficacy function gastrointestinal gold haemopoietic human hydroxychloroquine immune Immunology improvement increased induced inflammatory inhibition injection interleukin-1 interventions intra-articular Journal of Rheumatology leflunomide long-term Lorig lymphocytes meloxicam metabolism methotrexate mg/day mice minocycline monoclonal antibody months murine nabumetone naproxen necrosis factor nitrogen mustard NSAIDs osmic acid osteoarthritis outcome pain patients treated patients with rheumatoid piroxicam placebo production programme prostaglandin protein RA patients randomized receptor reduced renal response Rheumatic Diseases Rheumatism 37 rheumatoid arthritis Scandinavian Journal serum side-effects significant SMARDs stem cells sulphasalazine supplement synovectomy synovial synovium synthesis tenidap tetracyclines therapeutic tissue toxicity treatment arms treatment of rheumatoid versus vitro yttrium